Journal
BLOOD
Volume 116, Issue 25, Pages 5465-5475Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-05-267096
Keywords
-
Categories
Funding
- Ministerio de Educacion y Ciencia [SAF2007-65 957-C02-02, AP2005-3972]
- Ministerio de Ciencia e Innovacion [SAF2008-03 871]
- Fondo de Investigaciones Sanitarias [RTICC RD06/0020/0107]
- Fundacion Cientifica de la Asociacion Espanola contra el Cancer, Spain
Ask authors/readers for more resources
The Polycomb group (PcG) of proteins is a major mechanism of epigenetic regulation that has been broadly linked to cancer. This system can repress gene expression by chromatin modification and is essential for establishing cell identity. PcG proteins are important for stem cell function and differentiation and have a profound impact during hematopoiesis. In recent years, several published studies have deepened our knowledge of the biology of the PcG in health and disease. In this article, we review the current understanding of the mechanisms of PcG-mediated repression and their relation to DNA methylation, and we discuss the role of the PcG system in hematopoiesis and hematologic malignancies. We suggest that alteration of different PcG members is a frequent event in leukemia and lymphomas that confers the stem cell properties on tumor cells. Thus, drugs targeting Polycomb complexes could be useful for treating patients with these diseases. (Blood. 2010; 116(25): 5465-5475)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available